NCT02310750

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	PF-06700841 oral solution/suspension	Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
OTHER	Placebo	Matching placebo given during the single ascending and multiple dose periods
DRUG	PF-06700841 tablet	PF-06700841 tablet formulation administered during the bioavailability / food effect investigation

Timeline

• Start date: 2014-11-01
• Primary completion: 2016-01-01
• Completion: 2016-02-01
• First posted: 2014-12-08
• Last updated: 2017-03-08
• Results posted: 2017-03-08

Locations

1 site across 1 country: United States